Concepts (264)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Macular Degeneration | 14 | 2024 | 59 | 9.750 |
Why?
|
| Tomography, Optical Coherence | 24 | 2024 | 130 | 6.790 |
Why?
|
| Metformin | 8 | 2024 | 128 | 6.320 |
Why?
|
| Diabetic Retinopathy | 10 | 2024 | 87 | 6.010 |
Why?
|
| Wet Macular Degeneration | 7 | 2024 | 25 | 4.770 |
Why?
|
| Choroidal Neovascularization | 10 | 2023 | 31 | 4.630 |
Why?
|
| Retinal Detachment | 10 | 2023 | 66 | 4.340 |
Why?
|
| Fluorescein Angiography | 20 | 2023 | 96 | 4.210 |
Why?
|
| Geographic Atrophy | 5 | 2024 | 11 | 4.130 |
Why?
|
| Visual Acuity | 13 | 2024 | 194 | 3.830 |
Why?
|
| Retinal Vessels | 8 | 2023 | 58 | 3.440 |
Why?
|
| Choroid | 12 | 2024 | 33 | 3.220 |
Why?
|
| Vitrectomy | 7 | 2024 | 52 | 3.180 |
Why?
|
| Retinal Diseases | 6 | 2022 | 90 | 3.090 |
Why?
|
| Diabetes Mellitus | 6 | 2024 | 806 | 3.080 |
Why?
|
| Retinal Perforations | 5 | 2024 | 19 | 2.720 |
Why?
|
| Gastrointestinal Microbiome | 5 | 2022 | 455 | 2.640 |
Why?
|
| Retina | 10 | 2024 | 213 | 2.460 |
Why?
|
| Endophthalmitis | 4 | 2023 | 21 | 1.920 |
Why?
|
| Capillaries | 3 | 2022 | 91 | 1.720 |
Why?
|
| Macula Lutea | 3 | 2023 | 19 | 1.710 |
Why?
|
| Retinal Necrosis Syndrome, Acute | 2 | 2021 | 5 | 1.490 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2023 | 378 | 1.370 |
Why?
|
| Diabetes Mellitus, Type 2 | 3 | 2023 | 1373 | 1.330 |
Why?
|
| Ischemia | 2 | 2021 | 243 | 1.300 |
Why?
|
| Humans | 65 | 2024 | 86644 | 1.250 |
Why?
|
| Case-Control Studies | 7 | 2024 | 1805 | 1.140 |
Why?
|
| Anti-Bacterial Agents | 2 | 2023 | 746 | 1.130 |
Why?
|
| Macular Edema | 4 | 2022 | 50 | 1.130 |
Why?
|
| Retinopathy of Prematurity | 2 | 2020 | 66 | 1.120 |
Why?
|
| Healthy Volunteers | 3 | 2022 | 143 | 1.080 |
Why?
|
| Vision Disorders | 3 | 2023 | 75 | 1.050 |
Why?
|
| Microbiota | 2 | 2022 | 381 | 1.030 |
Why?
|
| Fovea Centralis | 2 | 2021 | 21 | 1.010 |
Why?
|
| Ophthalmoscopy | 3 | 2019 | 12 | 0.980 |
Why?
|
| Glycogen Storage Disease Type IIb | 1 | 2023 | 1 | 0.960 |
Why?
|
| Diet, High-Fat | 2 | 2022 | 114 | 0.960 |
Why?
|
| Uveitis | 2 | 2022 | 29 | 0.930 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2023 | 4 | 0.930 |
Why?
|
| Hemangioblastoma | 2 | 2020 | 12 | 0.910 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2020 | 17 | 0.910 |
Why?
|
| Ozone | 1 | 2022 | 8 | 0.890 |
Why?
|
| Vascular Endothelial Growth Factor A | 5 | 2024 | 407 | 0.890 |
Why?
|
| Cardiovascular Agents | 1 | 2023 | 56 | 0.890 |
Why?
|
| Retinal Telangiectasis | 1 | 2022 | 5 | 0.870 |
Why?
|
| Optics and Photonics | 2 | 2019 | 27 | 0.860 |
Why?
|
| Prospective Studies | 9 | 2024 | 4214 | 0.860 |
Why?
|
| Neuroprotective Agents | 1 | 2022 | 94 | 0.840 |
Why?
|
| Glaucoma, Open-Angle | 1 | 2022 | 17 | 0.830 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2023 | 206 | 0.820 |
Why?
|
| Autoimmune Diseases | 1 | 2023 | 241 | 0.810 |
Why?
|
| Retinal Neovascularization | 1 | 2021 | 5 | 0.800 |
Why?
|
| von Willebrand Diseases | 1 | 2021 | 6 | 0.800 |
Why?
|
| Medicare | 4 | 2024 | 410 | 0.740 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 2 | 2018 | 16 | 0.730 |
Why?
|
| Vitelliform Macular Dystrophy | 1 | 2019 | 1 | 0.710 |
Why?
|
| Optic Nerve Diseases | 1 | 2019 | 18 | 0.710 |
Why?
|
| Eye Infections, Viral | 1 | 2019 | 5 | 0.700 |
Why?
|
| Oculomotor Nerve Diseases | 1 | 2019 | 7 | 0.700 |
Why?
|
| Microbial Sensitivity Tests | 1 | 2019 | 143 | 0.700 |
Why?
|
| Herpes Zoster Ophthalmicus | 1 | 2019 | 6 | 0.700 |
Why?
|
| Encephalitis, Varicella Zoster | 1 | 2019 | 6 | 0.700 |
Why?
|
| Nerve Fibers | 1 | 2019 | 46 | 0.700 |
Why?
|
| Basement Membrane | 1 | 2019 | 54 | 0.690 |
Why?
|
| Aged | 17 | 2024 | 18415 | 0.690 |
Why?
|
| Herpesvirus 3, Human | 1 | 2019 | 43 | 0.680 |
Why?
|
| Angiogenesis Inhibitors | 4 | 2024 | 311 | 0.670 |
Why?
|
| Middle Aged | 20 | 2024 | 25028 | 0.650 |
Why?
|
| Eye Diseases | 1 | 2018 | 53 | 0.650 |
Why?
|
| Disease Management | 1 | 2020 | 327 | 0.650 |
Why?
|
| Scleral Buckling | 2 | 2016 | 18 | 0.630 |
Why?
|
| Male | 24 | 2024 | 40966 | 0.630 |
Why?
|
| Crohn Disease | 1 | 2023 | 730 | 0.600 |
Why?
|
| Staphylococcal Infections | 1 | 2019 | 255 | 0.590 |
Why?
|
| Staphylococcus aureus | 1 | 2019 | 263 | 0.580 |
Why?
|
| United States | 6 | 2024 | 6672 | 0.570 |
Why?
|
| Multimodal Imaging | 3 | 2023 | 110 | 0.550 |
Why?
|
| Retrospective Studies | 14 | 2024 | 8489 | 0.550 |
Why?
|
| Animals | 13 | 2023 | 26582 | 0.520 |
Why?
|
| Young Adult | 9 | 2021 | 5976 | 0.520 |
Why?
|
| Hypoglycemic Agents | 3 | 2024 | 378 | 0.510 |
Why?
|
| Female | 19 | 2024 | 44533 | 0.500 |
Why?
|
| Lasers | 4 | 2021 | 106 | 0.490 |
Why?
|
| Hypertension | 1 | 2023 | 1141 | 0.490 |
Why?
|
| Fundus Oculi | 7 | 2023 | 33 | 0.480 |
Why?
|
| Transcriptome | 3 | 2022 | 580 | 0.460 |
Why?
|
| International Classification of Diseases | 2 | 2024 | 69 | 0.460 |
Why?
|
| Risk Assessment | 1 | 2021 | 2261 | 0.460 |
Why?
|
| Levodopa | 2 | 2023 | 36 | 0.460 |
Why?
|
| Postoperative Complications | 3 | 2023 | 2207 | 0.450 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2022 | 12 | 0.440 |
Why?
|
| Cross-Sectional Studies | 3 | 2023 | 1621 | 0.430 |
Why?
|
| Optical Imaging | 1 | 2012 | 48 | 0.420 |
Why?
|
| Mice | 6 | 2023 | 11352 | 0.420 |
Why?
|
| Adult | 16 | 2023 | 25648 | 0.410 |
Why?
|
| Vitreous Detachment | 2 | 2023 | 3 | 0.390 |
Why?
|
| Vitreous Hemorrhage | 2 | 2023 | 11 | 0.390 |
Why?
|
| Vitreous Body | 3 | 2023 | 54 | 0.380 |
Why?
|
| Regional Blood Flow | 2 | 2021 | 197 | 0.370 |
Why?
|
| Polyps | 2 | 2023 | 28 | 0.370 |
Why?
|
| Ophthalmologic Surgical Procedures | 2 | 2020 | 25 | 0.370 |
Why?
|
| Retinal Vein Occlusion | 2 | 2022 | 8 | 0.350 |
Why?
|
| Computational Biology | 2 | 2023 | 528 | 0.350 |
Why?
|
| Hypertension, Pulmonary | 1 | 2012 | 346 | 0.330 |
Why?
|
| Blood-Retinal Barrier | 1 | 2008 | 4 | 0.320 |
Why?
|
| Treatment Outcome | 7 | 2024 | 7993 | 0.320 |
Why?
|
| Antimicrobial Cationic Peptides | 1 | 2008 | 13 | 0.320 |
Why?
|
| Choroiditis | 2 | 2018 | 7 | 0.320 |
Why?
|
| Blood Proteins | 1 | 2008 | 144 | 0.310 |
Why?
|
| Capillary Permeability | 1 | 2008 | 130 | 0.300 |
Why?
|
| Mice, Inbred C57BL | 3 | 2022 | 3092 | 0.280 |
Why?
|
| Disease Models, Animal | 3 | 2021 | 2232 | 0.260 |
Why?
|
| Methyldopa | 1 | 2024 | 3 | 0.250 |
Why?
|
| Carrier Proteins | 1 | 2008 | 673 | 0.240 |
Why?
|
| Immunotherapy | 2 | 2021 | 629 | 0.240 |
Why?
|
| Epiretinal Membrane | 1 | 2023 | 2 | 0.240 |
Why?
|
| Sulfonylurea Compounds | 1 | 2024 | 64 | 0.240 |
Why?
|
| Fluoroquinolones | 1 | 2023 | 22 | 0.230 |
Why?
|
| Aminoglycosides | 1 | 2023 | 32 | 0.230 |
Why?
|
| Drug Repositioning | 1 | 2023 | 22 | 0.230 |
Why?
|
| Retinal Drusen | 1 | 2023 | 1 | 0.230 |
Why?
|
| Choroid Diseases | 1 | 2023 | 5 | 0.230 |
Why?
|
| Aphakia | 1 | 2023 | 10 | 0.230 |
Why?
|
| Laser Coagulation | 2 | 2021 | 54 | 0.230 |
Why?
|
| Data Mining | 1 | 2023 | 42 | 0.230 |
Why?
|
| Paraquat | 1 | 2022 | 9 | 0.220 |
Why?
|
| Aged, 80 and over | 3 | 2024 | 6509 | 0.220 |
Why?
|
| Neuroprotection | 1 | 2022 | 7 | 0.220 |
Why?
|
| Cataract Extraction | 1 | 2023 | 31 | 0.220 |
Why?
|
| RNA, Ribosomal, 16S | 1 | 2023 | 241 | 0.220 |
Why?
|
| Morbidity | 1 | 2023 | 148 | 0.220 |
Why?
|
| Risk Factors | 3 | 2024 | 5417 | 0.220 |
Why?
|
| Microbiological Techniques | 1 | 2022 | 24 | 0.220 |
Why?
|
| Eye | 2 | 2023 | 111 | 0.210 |
Why?
|
| Cataract | 1 | 2023 | 86 | 0.210 |
Why?
|
| Lens, Crystalline | 1 | 2023 | 69 | 0.210 |
Why?
|
| Intravitreal Injections | 2 | 2019 | 67 | 0.200 |
Why?
|
| Prednisolone | 2 | 2019 | 41 | 0.200 |
Why?
|
| Infant, Newborn | 2 | 2020 | 2380 | 0.200 |
Why?
|
| Light Coagulation | 1 | 2021 | 6 | 0.200 |
Why?
|
| Germ-Free Life | 1 | 2021 | 69 | 0.200 |
Why?
|
| von Willebrand Factor | 1 | 2021 | 37 | 0.200 |
Why?
|
| Dysbiosis | 1 | 2022 | 70 | 0.200 |
Why?
|
| Antioxidants | 1 | 2022 | 223 | 0.200 |
Why?
|
| Lipids | 1 | 2022 | 269 | 0.200 |
Why?
|
| Graves Ophthalmopathy | 1 | 2020 | 4 | 0.190 |
Why?
|
| Scleritis | 1 | 2020 | 5 | 0.190 |
Why?
|
| Ethanol | 1 | 2022 | 249 | 0.180 |
Why?
|
| Incidence | 2 | 2023 | 1577 | 0.180 |
Why?
|
| Guidelines as Topic | 1 | 2021 | 162 | 0.180 |
Why?
|
| Proof of Concept Study | 1 | 2019 | 38 | 0.180 |
Why?
|
| Societies, Medical | 2 | 2021 | 572 | 0.180 |
Why?
|
| Retinal Neoplasms | 1 | 2019 | 10 | 0.180 |
Why?
|
| Sequence Analysis, RNA | 1 | 2021 | 217 | 0.180 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2019 | 74 | 0.180 |
Why?
|
| Foscarnet | 1 | 2019 | 12 | 0.180 |
Why?
|
| Aqueous Humor | 1 | 2019 | 23 | 0.170 |
Why?
|
| Cerebrospinal Fluid | 1 | 2019 | 32 | 0.170 |
Why?
|
| Gestational Age | 1 | 2020 | 311 | 0.170 |
Why?
|
| Angiography | 1 | 2020 | 208 | 0.170 |
Why?
|
| Drug Therapy, Combination | 2 | 2019 | 894 | 0.170 |
Why?
|
| Glucocorticoids | 2 | 2019 | 352 | 0.170 |
Why?
|
| Insulin | 1 | 2024 | 1160 | 0.160 |
Why?
|
| Infusions, Intravenous | 1 | 2019 | 429 | 0.160 |
Why?
|
| Swine | 1 | 2019 | 555 | 0.160 |
Why?
|
| Infant, Premature | 1 | 2020 | 290 | 0.160 |
Why?
|
| Pigment Epithelium of Eye | 1 | 2017 | 13 | 0.160 |
Why?
|
| Photography | 1 | 2018 | 37 | 0.160 |
Why?
|
| Feasibility Studies | 1 | 2019 | 751 | 0.150 |
Why?
|
| Retinal Cone Photoreceptor Cells | 1 | 2018 | 42 | 0.150 |
Why?
|
| Environment | 1 | 2018 | 219 | 0.150 |
Why?
|
| Polymerase Chain Reaction | 1 | 2019 | 927 | 0.150 |
Why?
|
| Host-Pathogen Interactions | 1 | 2018 | 231 | 0.140 |
Why?
|
| Reoperation | 1 | 2018 | 597 | 0.140 |
Why?
|
| Angiomatosis | 1 | 2015 | 5 | 0.140 |
Why?
|
| Neurocutaneous Syndromes | 1 | 2015 | 12 | 0.130 |
Why?
|
| Algorithms | 1 | 2024 | 1830 | 0.130 |
Why?
|
| Light | 1 | 2016 | 289 | 0.130 |
Why?
|
| Antiviral Agents | 1 | 2019 | 510 | 0.130 |
Why?
|
| Arteriovenous Fistula | 1 | 2015 | 52 | 0.130 |
Why?
|
| Chicago | 1 | 2019 | 1379 | 0.130 |
Why?
|
| Neoplasms | 2 | 2021 | 2898 | 0.120 |
Why?
|
| Bevacizumab | 1 | 2015 | 281 | 0.120 |
Why?
|
| Alternaria | 1 | 2013 | 1 | 0.120 |
Why?
|
| Alternariosis | 1 | 2013 | 1 | 0.120 |
Why?
|
| Corneal Ulcer | 1 | 2013 | 6 | 0.120 |
Why?
|
| Corneal Transplantation | 1 | 2013 | 9 | 0.120 |
Why?
|
| Referral and Consultation | 1 | 2016 | 328 | 0.120 |
Why?
|
| Eye Infections, Fungal | 1 | 2013 | 14 | 0.120 |
Why?
|
| Infant | 1 | 2020 | 3047 | 0.120 |
Why?
|
| Skin Diseases | 1 | 2015 | 166 | 0.120 |
Why?
|
| Time Factors | 2 | 2019 | 5210 | 0.120 |
Why?
|
| Chorioretinitis | 1 | 2013 | 10 | 0.110 |
Why?
|
| Eye Injuries | 1 | 2013 | 15 | 0.110 |
Why?
|
| Infrared Rays | 1 | 2012 | 17 | 0.110 |
Why?
|
| Mutation | 1 | 2023 | 3968 | 0.110 |
Why?
|
| Organ Size | 1 | 2012 | 364 | 0.100 |
Why?
|
| Rats, Inbred BN | 2 | 2008 | 37 | 0.100 |
Why?
|
| Quality of Life | 1 | 2019 | 1585 | 0.100 |
Why?
|
| Porphyrins | 2 | 2009 | 39 | 0.090 |
Why?
|
| Photosensitizing Agents | 2 | 2009 | 48 | 0.090 |
Why?
|
| Choroid Neoplasms | 1 | 2009 | 6 | 0.090 |
Why?
|
| Adolescent | 3 | 2018 | 8981 | 0.090 |
Why?
|
| Proton Therapy | 1 | 2009 | 27 | 0.090 |
Why?
|
| Hemangioma | 1 | 2009 | 60 | 0.090 |
Why?
|
| Photochemotherapy | 2 | 2009 | 97 | 0.090 |
Why?
|
| Evans Blue | 1 | 2008 | 5 | 0.080 |
Why?
|
| Monocyte Chemoattractant Proteins | 1 | 2008 | 3 | 0.080 |
Why?
|
| Aprotinin | 1 | 2008 | 26 | 0.080 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2008 | 28 | 0.080 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 1801 | 0.080 |
Why?
|
| Rats, Long-Evans | 1 | 2008 | 48 | 0.080 |
Why?
|
| Diabetes Mellitus, Experimental | 1 | 2008 | 190 | 0.070 |
Why?
|
| Ciliary Body | 1 | 2006 | 7 | 0.070 |
Why?
|
| Interleukin-1 | 1 | 2006 | 71 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2006 | 47 | 0.070 |
Why?
|
| Fibroblast Growth Factor 2 | 1 | 2006 | 57 | 0.070 |
Why?
|
| Acute Disease | 2 | 2018 | 826 | 0.070 |
Why?
|
| Ophthalmoscopes | 1 | 2005 | 1 | 0.070 |
Why?
|
| Laser Therapy | 1 | 2006 | 142 | 0.060 |
Why?
|
| Child | 3 | 2023 | 6927 | 0.060 |
Why?
|
| Rats | 2 | 2008 | 3990 | 0.060 |
Why?
|
| Ependymoglial Cells | 1 | 2023 | 5 | 0.060 |
Why?
|
| Gliosis | 1 | 2023 | 35 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 683 | 0.050 |
Why?
|
| Japan | 1 | 2023 | 307 | 0.050 |
Why?
|
| Life Style | 1 | 2023 | 189 | 0.050 |
Why?
|
| Strabismus | 1 | 2020 | 10 | 0.050 |
Why?
|
| Oculomotor Muscles | 1 | 2020 | 28 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2023 | 243 | 0.050 |
Why?
|
| Aging | 1 | 2023 | 691 | 0.040 |
Why?
|
| Neurotoxicity Syndromes | 1 | 2017 | 28 | 0.040 |
Why?
|
| Inflammation | 1 | 2023 | 920 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2023 | 3612 | 0.040 |
Why?
|
| Cohort Studies | 1 | 2023 | 2767 | 0.040 |
Why?
|
| Reproducibility of Results | 2 | 2017 | 2705 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 257 | 0.030 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 3640 | 0.030 |
Why?
|
| Evidence-Based Medicine | 1 | 2017 | 429 | 0.030 |
Why?
|
| Voriconazole | 1 | 2013 | 17 | 0.030 |
Why?
|
| Administration, Topical | 1 | 2013 | 95 | 0.030 |
Why?
|
| Antifungal Agents | 1 | 2013 | 117 | 0.030 |
Why?
|
| Administration, Oral | 1 | 2013 | 684 | 0.030 |
Why?
|
| Wounds, Gunshot | 1 | 2013 | 71 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2017 | 1036 | 0.020 |
Why?
|
| Papilledema | 1 | 2009 | 3 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2009 | 468 | 0.020 |
Why?
|
| Photoreceptor Cells, Vertebrate | 1 | 2006 | 9 | 0.020 |
Why?
|
| Sclera | 1 | 2006 | 11 | 0.020 |
Why?
|
| Intraocular Pressure | 1 | 2006 | 54 | 0.020 |
Why?
|
| Longitudinal Studies | 1 | 2009 | 1019 | 0.020 |
Why?
|
| Neuroglia | 1 | 2006 | 104 | 0.020 |
Why?
|
| Tissue Distribution | 1 | 2006 | 290 | 0.020 |
Why?
|
| Retinal Ganglion Cells | 1 | 2006 | 66 | 0.020 |
Why?
|
| Astrocytes | 1 | 2006 | 139 | 0.020 |
Why?
|
| Microscopy, Electron | 1 | 2006 | 503 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2006 | 376 | 0.020 |
Why?
|
| Rabbits | 1 | 2006 | 636 | 0.020 |
Why?
|
| Confidence Intervals | 1 | 2005 | 229 | 0.020 |
Why?
|
| Observer Variation | 1 | 2005 | 602 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1753 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1981 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2005 | 1991 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1683 | 0.010 |
Why?
|